New Combination Therapy Explored for Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC) is a devastating disease, often diagnosed at advanced stages, where treatment options can be limited. Standard chemotherapy regimens, like paclitaxel and carboplatin, are foundational but often have limited long-term efficacy. This study aimed to evaluate the safety and preliminary efficacy of adding CP-751,871 to standard first-line chemotherapy for advanced NSCLC.

The provided study record details the design and interventions but does not include specific efficacy or safety results from this completed trial. Typically, a Phase 2 study like this would assess endpoints such as overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse event profiles to determine the clinical benefit. > The primary objective was to determine the safety and tolerability of the combination, and to evaluate preliminary anti-tumor activity, though specific data from this 282 patient trial are not available in this record. Without the results, it is not possible to quantitatively compare the treatment arms or report specific p-values or response rates. The study completed in 2011, suggesting that results may have been published elsewhere, but are not part of this abstract.